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Objectives. Treatment with pegylated interferon and ribavirin may prevent progression of liver disease among
patients with chronic hepatitis C virus infection (HCV). Treatment initiation is based on published clinical
eligibility criteria, patients’ willingness to undergo treatment and likelihood of success. We examined
treatment eligibility in a cohort of Alaska Native and American Indian persons with chronic HCV infection.
Study design. Retrospective cohort study.
Methods. Medical records of all treatment naı̈ve HCV RNA positive patients given an appointment by
hepatology specialty clinic staff in 2003 and 2007 were evaluated by a hepatology provider to investigate
documented reasons for treatment deferral.
Results. Treatment was initiated in 4 of 94 patients (4%) in 2003 and 14 of 146 patients (10%) in 2007.
Major reasons for treatment deferral in 2003 versus 2007 included inconsistent appointment attendance
(36% of deferrals vs. 18%), active substance abuse (17% vs. 22%), patient decision (17% vs. 27%), liver biopsy
without fibrosis or normal ALT (8% vs. 3%), uncontrolled psychiatric condition (7% vs. 7%) and concurrent
medical condition (6% vs. 9%). There was significant improvement in proportion of appointments attended
in 2007 versus 2003 (76% vs. 67%, p 0.04) and the percentage of patients attending at least 1 appointment
(84% vs. 66%, p 0.002).
Conclusions. Multiple reasons for treatment deferral were documented. Despite a significant improvement
in hepatology clinic attendance and an increase in the number of patients started on treatment in 2007
compared to 2003, the overall percentage of those treated remained low.
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A
n estimated 4.1 million people in the United
States are chronically infected with hepatitis C
virus (HCV), primarily via intravenous drug
use or blood transfusion prior to screening of the
blood supply in 1992 (1). These persons are at risk for
development of cirrhosis, liver failure and hepatocellular
carcinoma. Treatment for HCV is effective in only
approximately 50% of patients. The currently approved
treatment is a combination of pegylated interferon
and ribavirin for 2448 weeks, depending on genotype.
Recent licensing of 2 oral protease inhibitors, tela-
previr and boceprevir, is expected to improve treatment
response significantly in persons with genotype 1 when
combined with pegylated interferon and ribavirin, as
well as decrease duration of treatment in many patients.
Antiviral treatment is initiated in hopes of achieving a
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sustained virologic response, defined as undetectable
HCV RNA 6 months post-treatment, and preventing
further progression of liver disease (2).
Not all patients infected with HCV are good candidates
for current antiviral treatment. In those patients willing
to undergo treatment, initiation of therapy is based on the
likelihood of treatment success. Current and previous
practice guidelines published by the American Associa-
tion for the Study of Liver Diseases list characteristics
of persons for whom therapy ‘‘is widely accepted,’’ ‘‘is
currently contraindicated’’ or ‘‘should be individualized
(2,3).’’ Guidelines published prior to 2004 proposed
eligibility criteria based on similar concepts (4). These
‘‘eligibility’’ criteria are used by medical providers to
ensure that those individuals most likely to benefit receive
treatment.
In a population-based longitudinal cohort study
of Alaska Native and American Indian persons infected
with HCV, a relatively small number of patients have
received HCV treatment despite increased identification
and available institutional resources (5). Utility and
applicability of published eligibility criteria for HCV
treatment have not been studied in Alaska Native and
American Indian persons. The goal of this retrospective
cohort study was to assess treatment acceptance in
patients based on documented behaviours and determine
which of the published treatment eligibility criteria most
influenced the provider’s decision to start treatment.
Materials and methods
Patients
Alaska Native and American Indian persons living
in Alaska are eligible for health care in a prepaid
managed healthcare system through the Alaska Native
Tribal Health Consortium and Alaska Native Medical
Center (ANMC), a tertiary referral hospital in Ancho-
rage. Since 1995, the Alaska Native Tribal Health
Consortium Liver Disease and Hepatitis Program has
enrolled 1,234 people into a longitudinal outcomes
cohort study of chronic HCV infection. All partici-
pants had a positive anti-HCV test confirmed either
by recombinant immunoblot assay or HCV RNA by
polymerase chain reaction. Of 986 persons in this
study population living on June 1, 2010, most resided
in urban areas, including 60% in Anchorage, 15% in
Fairbanks and 11% in Juneau and Sitka. Details of this
patient cohort have been previously described, including
clinical outcomes through 2005 (6).
Approval for this study was obtained from
the Institutional Review Boards of the Alaska Area
Indian Health Service, the University of Washington
Medical Center and the Centers for Disease Control and
Prevention and appropriate Alaska Native Health Cor-
poration boards. All patients provided written informed
consent that included permission for chart review of
previous records.
Study design
Medical records of all treatment naı̈ve HCV RNA positive
patients given appointments in the hepatology specialty
clinic at ANMC over 2 specific 1-year periods (January
1December 31, 2003, and January 1December 31,
2007) were evaluated by a hepatology provider (physician
or nurse practitioner) to examine treatment eligibility
based on clinical guidelines, patient preference and patient
attendance at appointments. These 1-year periods were
selected 4 years apart in order to investigate differences
in treatment eligibility over time. In addition to pertinent
history, physical examination and laboratory testing,
hepatology clinic providers routinely discussed the nature
of HCV infection, including long-term prognosis, routine
follow-up recommendations, the role of liver biopsy,
indications for treatment and detailed discussions of the
treatment regimen and potential side effects. Documented
patient behaviours and responses were also used to
establish patient acceptance of treatment.
The hepatology clinic was staffed by 2 physicians
and 1 nurse practitioner for 5 half-day clinics weekly
in 2003 and by 2 physicians and 2 nurse practitioners
for 7 half-day clinics weekly in 2007. One of the 2 nurse
practitioners was hired in 2006 and dedicated to hepatitis
C management, including treatment. Beginning in 2002,
all patients with chronic HCV infection living in the
Anchorage area were sent a letter biannually recomm-
ending that they make a follow-up clinic appointment
and have their liver function tests performed. Most
follow-up appointments were made by clinic staff at
the request of patients who contacted the clinic. Some
patients who did not make clinic appointments or have
liver function tests performed after receiving a reminder
letter were contacted by clinic staff and offered an
appointment, which was made with patient agreement.
Likewise, patients referred by other providers for a
new clinic appointment were contacted by clinic staff
and offered an appointment, which was made with their
agreement. Most patients seen in the ANMC hepatology
clinic in Anchorage resided in the Anchorage area. Those
referred from other areas of the state generally had travel
to Anchorage provided free of charge to the patient.
Laboratory testing and histologic evaluation
Alanine aminotransferase (ALT) testing was performed at
the ANMC laboratory (Anchorage, AK) on an Aeroset
Chemistry analyzer (Abbott Laboratories, USA). An
ALT level of lower than 40 U/L was defined as normal.
Testing for HCV RNA and genotype was performed at
the University of Washington as previously described (7).
Liver biopsy was performed only for clinical reasons,
primarily to evaluate for possible treatment. Liver biopsy
slides were evaluated by at least 1 of the 2 physicians
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(SL or BM), both practicing hepatologists, for clinical
purposes. In addition, biopsy slides were evaluated by a
study pathologist (HD) who was blinded to patient
identity and demographic, clinical and biological data.
Fibrosis was evaluated using the Knodell system (8).
Statistical analysis
Patient data were analysed for characteristics that inclu-
ded gender, age, years since diagnosis, genotype, ALT
level, Knodell fibrosis score, risk factors (injection drug
use, blood transfusion and other) and alcohol consump-
tion at the time of entry into the study (consumption of
any alcohol and consumption of 50 g/day). Statistical
analysis was performed to compare characteristics of
persons with consistent hepatology clinic appointment
attendance to those with inconsistent attendance for
given appointments. Additionally, documented reasons
for treatment eligibility were compared in 2003 and 2007
using the likelihood ratio chi-square statistic. We used
the Cochran-Armitage test for trend to examine if the
percentage of persons who attended their appointments
varied with age, ALT level and time since diagnosis. All
p-values were 2-sided and values B0.05 were considered
statistically significant. The p-values were exact when
sample size necessitated. All analyses were conducted




Treatment with pegylated interferon and ribavirin
was initiated in 4 of 94 patients (4%) in 2003 and 14 of
146 patients (10%) in 2007. Of the 4 patients started
on treatment in 2003, 1 achieved a sustained virologic
response; 1 discontinued treatment due to side effects;
treatment failed in another, and the fourth relapsed
after achieving an end of treatment response. Of the
14 patients started on treatment in 2007, 4 achieved a
sustained virologic response; 8 discontinued treatment
due to side effects; treatment failed in 1 and 1 relapsed.
Treatment eligibility 2003
In 2003, we identified 94 treatment naı̈ve patients who
were scheduled for 175 appointments in the ANMC
hepatology clinic. Of 19 patients who were scheduled
for multiple appointments, 14 did not attend any of
the appointments and 5 attended at least one of the
scheduled appointments; attendance at this appointment
was used by the provider to evaluate for treatment
eligibility. Thirty-two of the 94 patients (34%) did not
attend any of the appointments and, thus, were consid-
ered not eligible for treatment during the study period
by the provider. Of the 90 patients not treated, reasons
for providers deferring treatment were inability to attend
scheduled appointments, 32 (36%); documented alcohol
or drug abuse within 6 months of evaluation, 16 (17%);
patient decision to defer treatment despite being con-
sidered an eligible candidate, 16 (17%); liver biopsy
without fibrosis or normal ALT, 8 (8%); documented
uncontrolled psychiatric condition, 7 (7%); concurrent
medical condition precluding treatment, 6 (6%); decom-
pensated cirrhosis, 3 (3%), and age 65 years, 2 (2%)
(Table I).
Treatment eligibility 2007
In 2007, we identified 146 treatment naı̈ve patients who
were scheduled for 278 appointments in the ANMC
hepatology clinic. Of 45 patients who had multiple
scheduled appointments, 2 attended none of them and
43 attended at least 1. Overall, 24 of the 146 patients
(16%) did not attend any scheduled appointments. Of the
132 patients not treated, reasons for providers deferring
treatment were patient decision to defer, 36 (27%);
alcohol or drug abuse within 6 months of evaluation,
29 (22%); inability to attend scheduled appointments, 24
(18%); concurrent medical condition precluding treat-
ment, 12 (9%); uncontrolled psychiatric condition, 9
(6%); decompensated cirrhosis, 7 (5%); patients consider-
ing or planning treatment but not yet started, 7 (5%);
liver biopsy without fibrosis or normal ALT, 4 (3%); age
65 years, 2 (1%), and other, 2 (1%) (Table I).
Characteristics of patients who attended scheduled
clinic appointments (2003 and 2007)
The proportion of appointments attended increased
significantly in 2007 versus 2003 (73% vs. 67%, respec-
tively, p 0.04). Likewise, the percentage of patients
who attended at least 1 scheduled appointment increased
in 2007 versus 2003 (84% vs. 66%, p 0.002) (Table II).
In 2003, persons with a history of intravenous drug
use were significantly less likely to attend clinic appoint-
ments than those with other risk factors (p 0.04).
In 2007, there was a significant difference in time since
diagnosis among those who attended clinic appoint-
ments. Among persons diagnosed with HCV infection
B3 years prior to the appointment, 93% attended at
least 1 appointment compared to 86% and 73% for
diagnosis 37 and ]8 years prior, respectively
(p 0.009). There was no significant difference in other
characteristics in either year among those who attended
scheduled appointments (Table III).
Discussion
Between 2003 and 2007, the number of chronic HCV-
infected persons who made appointments in the ANMC
hepatology clinic increased by over 50% and the number
of appointments attended nearly doubled. Likewise,
the number of patients started on HCV treatment more
than tripled between 2003 and 2007, increasing from
4 (4%) to 14 (10%).
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Of those who attended clinic appointments but were
not treated, we found little difference in the reasons
patients were not started on HCV treatment between
2003 and 2007. Substance abuse and individual patient
decision to defer treatment remained the 2 most common
reasons (1636%), whereas smaller percentages had
concurrent medical or psychiatric conditions, liver biop-
sies without fibrosis or normal ALT and decompensated
cirrhosis.
Previous studies of HCV treatment eligibility have
reported similar findings, including low rates of treat-
ment. A large US Veterans Administration study exam-
ined a nationwide database of over 100,000 HCV-infected
patients and found that treatment was initiated in only
11.9% and completed in only 22.5% of those, which was
less than 2% of the whole cohort (9). A smaller Veterans
Administration study looked at the reasons for non-
treatment in 354 patients referred to a hepatology clinic,
70% of whom were not treated. The most common
reasons for non-treatment were non-adherence to follow-
up visit (24%), normal liver enzymes (14%), concurrent
medical problems (11%), alcohol and drug abuse (9%),
psychiatric problems (7%) and advanced liver disease
(7%) (10). A study of 293 patients at a teaching county
hospital in Cleveland, Ohio, found that 72% of patients
were not treated. Reasons included non-adherence (37%),
medical or psychiatric contraindications (34%), ongoing
substance abuse (13%), personal preference (11%) and
normal liver enzymes (5%) (11).
As we have identified more patients with HCV, the
number of appointments made in our hepatology clinic
has increased. Hepatology clinic appointments for HCV
at ANMC are made by referral for initial evaluation,
often by primary care providers, and directly by patients
for follow-up. We did not attempt to differentiate between
these reasons for making appointments in our study.
Table I. Reasons for non-treatment of Alaska Native and American Indian persons with chronic hepatitis C seen in a hepatology clinic
in 2003 and 2007
Reason 2003 (%) 2007 (%)
Inability to attend scheduled clinic appointments 32 (36%) 24 (16%)
Alcohol or drug abuse within 6 months 16 (17%) 29 (22%)
Patient decision to defer treatment 16 (17%) 36 (25%)
Liver biopsy without fibrosis or normal ALT 8 (8%) 4 (3%)
Uncontrolled psychiatric condition 7 (7%)a 9 (6%)b
Concurrent medical condition precluding treatment 6 (6%)c 12 (8%)d
Decompensated cirrhosis 3 (3%) 7 (5%)
Age 65 years 2 (2%) 2 (1%)
Considering or planning treatment 0 7 (5%)
Other 0 2 (1%)
Total 90 132
aIncludes bipolar disorder (2), depression, dementia and mental retardation.
bIncludes bipolar disorder (2), schizophrenia, depression and personality disorder (2).
cIncludes rheumatoid arthritis, seizure disorder, severe diabetes mellitus, systemic lupus erythematosis, chronic renal failure and severe
chronic back pain.
dIncludes cancer (2), myopathy, malabsorption syndrome, pregnancy, severe diabetes mellitus, chronic obstructive lung disease, severe
chronic back pain and autoimmune hepatitis.
Table II. Comparison of appointment attendance in a hepatology clinic by Alaska Native and American Indian persons between
2003 and 2007
Study year Number of appointments
Proportion of appointments
attended (%) Number of patients
Number of patients attending ]1
scheduled appointment (%)
2003 175 118 (67%) 94 62 (66%)a
2007 278 212 (76%) 146 122 (84%)a
p-valueb 0.04 0.002
Combined 453 73% (330) 240 77% (184)
aIf persons who were seen in both years are removed, those attending ]1 appointment were 64% (42/66) in 2003 vs. 86% (101/118) in
2007, p 0.002.
bp-value compares 2003 percentage vs. 2007 percentage.
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Several factors may explain why a significantly larger
percentage of patients attended appointments in 2007
compared to 2003. They include the hiring of an
additional nurse practitioner in 2006 who was dedicated
to HCV, resulting in a more aggressive approach on
our part to HCV management and treatment. Informa-
tion was not available regarding whether the patient
was initially seen by a physician or a nurse practitioner
but all patients were seen by a physician before treatment
was started. By 2007, many patients had been receiving
regular reminder letters to get laboratory and clinic
follow-up for several years.
The role of Native healers in appointment attendance
was not evaluated. Native healers were available in
the Primary Care Clinic at ANMC and their care
was coordinated with primary care providers. However,
records of visits with Native healers were not available on
patient charts, and we do not know if any of the patients
seen in the hepatology clinic sought advice from them.
Despite the increase in clinic appointments, the per-
centage of those who made appointments and were
subsequently started on treatment remained very small.
A more comprehensive team approach utilising pri-
mary care providers, mental health providers, social
workers and pharmacists, available in our primary care
center, as well as hepatology providers might increase
treatment numbers in a setting like Anchorage. A model
for increasing treatment numbers around the state could
be based on the rural University of New Mexico Project
ECHO program, which has provided care for hepatitis C
patients via audio and visual conferencing (12). With
the Food and Drug Administration approval of telaprevir
(13) and boceprevir (14), treatment for genotype 1 will
be significantly more effective. This likely will increase
the number of patients seeking treatment.
Patients attending appointments in 2007 were signifi-
cantly more likely to have been diagnosed with HCV
infection B3 years prior to the appointment, compared
Table III. The percentage of Alaska Native and American Indian persons with chronic hepatitis C virus (HCV) infection attending
hepatology clinic scheduled appointments in 2003 and 2007, according to demographic and HCV infection characteristics
2003 2007
Characteristic Level Attendance ratea p-value Attendance rate p-value
Sex Female 67% (34/51) 0.87 82% (61/74) 0.71
Male 65% (28/43) 85% (61/72)
Age B40 years 63% (19/30) 0.10 83% (25/30) 0.48
4049 years 56% (23/41) 88% (46/52)
]50 years 87% (20/23) 80% (51/64)
Time since diagnosis B3 years 80% (20/25) 0.26 93% (40/43) 0.009
37 years 59% (27/46) 86% (43/50)
]8 years 65% (15/23) 73% (38/52)
HCV genotype 1 61% (36/59) 0.41 81% (79/98) 0.15
2 74% (14/19) 81% (17/21)
3 75% (12/16) 99% (24/25)
ALT levelb B40 62% (16/26) 0.34 85% (33/39) 0.79
40 to B80 62% (21/34) 85% (50/59)
]80 73% (22/30) 87% (39/45)
Knodell fibrosis score 01 69% (22/32) 0.39 80% (41/51) 0.78
34 82% (9/11) 83% (15/18)
HCV risk factor for infection IVDUc 58% (35/60) 0.04e 80% (74/92) 0.17e
BTd 80% (12/15) 86% (12/14)
Other 78% (14/18) 90% (36/40)
Consume any alcohol Yes 64% (28/44) 0.71 82% (55/67) 0.66
No 67% (33/49) 85% (67/79)
History of 50 g/day of alcohol Yes 67% (23/34) 0.79 88% (34/41) 0.38
No 65% (39/60) 82% (86/105)
aPercent of patients attending ]1 appointment.
bALT, alanine aminotransferase, in units/liter.
cIVDU, intravenous drug use.
dBT, blood transfusion.
ep-value for IVDU vs. all others.
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to those with a longer time since diagnosis (p 0.009).
This also occurred in 2003 but was not statistically
significant. The reason for this is uncertain, but it is
possible that persons more recently diagnosed could be
more motivated to obtain information about their disease
than persons who have known about their diagnosis
for a longer period and may have already been seen in
the clinic.
We do not have an obvious explanation why persons
with the risk factor of intravenous drug use were
significantly less likely to attend appointments in 2003
compared to those with other risk factors. We found no
difference in risk factors among those who attended
appointments in 2007. We previously documented that a
history of intravenous drug use is the major risk factor for
HCV infection in this cohort; 60% gave this history (3).
However, we do not think this was a major factor since,
by 2007, 80% of persons with an intravenous drug
use history attended clinic appointments. Knowledge
of treatment side effects and other factors could have
influenced appointment attendance. We determined that
persons not attending clinic appointments were not
eligible for hepatitis C treatment during the study period,
as other investigators have done. It is conceivable, how-
ever, that a significant number of these patients were
actually eligible for treatment but were unable to attend
appointments for temporary personal reasons, such as
child care or other family issues, transportation difficulties
or work responsibilities. Investigation of reasons for not
attending appointments was not part of this study,
however.
This study was unique because it was population based
and evaluated a group whose health care needs have been
underserved. It was limited somewhat by the relatively
small study size. We also did not attempt to determine if
cultural factors influenced patient decisions to seek
treatment. Hepatitis C is primarily an urban disease in
Alaska due to a low rate of intravenous drug use in rural
villages; so, our results may not be applicable to rural
areas where specialty care and treatment are not always
available.
In conclusion, we found multiple reasons why treat-
ment was deferred in a cohort of Alaska Native and
American Indian persons with chronic HCV infection.
Despite a significant improvement in hepatology clinic
appointment attendance between 2003 and 2007 and an
increase in the number of patients started on treatment,
the overall percentage of those treated remained low.
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